Avian influenza present on P.E.I., but not a risk to general public, experts say
The virus has been present on the Island for years, and was recently confirmed to have infected a large number of dying and dead Canada geese in Vernon Bridge, P.E.I.
"It serves as a reminder that the virus is out there and it is circling," said Dr. Jill Wood, P.E.I.'s chief veterinary officer.
The highly contagious virus can be transmitted to birds and mammals, including humans. But the risk to the general public is low, Wood said.
"That being said, we're certainly cautioning people not to approach sick wildlife or handle ill wildlife," she said.
If someone needed to interact with sick or dead wildlife — like to remove a dead crow from their lawn, for example — Wood offered some advice: "Wear a mask, wear gloves, double bag it."
She also added that it's best to use a shovel and not your hands.
How the virus is spread
The H5N1 virus is spread by contact with bodily fluids, including feces, said Marguerite Cameron, communicable disease epidemiologist at the Chief Public Health Office.
While human infection is rare, it can occur through close contact with infected birds or heavily infected environments such as poultry farms, Cameron said.
Using personal protective equipment — or PPE — is very important to reduce exposure, she said.
Cameron said her advice to Islanders is to always keep distance from wild birds and wild animals.
"Don't handle them, don't pick them up, don't feed them," she said.
'The virus is out there. It's something to be aware of but it's not something that should consume your life or make you anxious,' says Wade Sweet. (Taylor O'Brien/CBC)
Islanders should also keep pets away from any animals that might be sick, dying or dead, as mammals can become infected by scavenging on dead birds, Cameron said.
"That's why it's important for pet owners especially to make sure that their pets are not accessing any sick or dead animals," she said.
If there is a dead bird or animal that Islanders feel concerned about, they can call the Forests, Fish and Wildlife division of the province's Department of Environment, Water and Climate Change.
Staying safe and healthy
In February, the Public Health Agency of Canada said it purchased 500,000 doses of a human vaccine to protect those most at risk of exposure to the virus.
P.E.I. will have access to this stockpile, Cameron said, adding that there is an allocation framework and a risk assessment to determine eligibility.
Currently, the national advisory committee on immunization does not have recommendations as to how the vaccine will be deployed more broadly, she said.
What Islanders can do is ensure they are up to date with their seasonal flu vaccine, Cameron said.
"While [seasonal flu] vaccine won't protect them against avian influenza, it will protect them from potentially getting a co-infection with avian influenza and seasonal flu," she said, adding that a co-infection could result in more critical illness.
The two flu viruses could also exchange genetic material, which could potentially result in a new influenza strain, she said.
"That is what we're really trying to avoid," she said.
Cameron says her advice to Islanders is to always keep distance from wild birds and wild animals. (Taylor O'Brien/CBC)
For Dr. Wade Sweet, a veterinarian at West Prince Veterinary Hospital, an avian influenza vaccine is something he said he would be interested in getting if it was offered.
Until then, he relies on basic biosecurity measures such as wearing clean coveralls, boots and gloves when handling birds.
For Islanders wondering about food safety, Sweet said cooked poultry, eggs and pasteurized dairy products are still safe to consume.
"Anything you see that's in the grocery store, it's been pasteurized... it's not going to infect you," he said.
It's important for pet owners especially to make sure that their pets are not accessing any sick or dead animals - Marguerite Cameron
Sweet said the risk to the general public is low, and Islanders shouldn't be overly concerned.
"The virus is out there. It's something to be aware of but it's not something that should consume your life or make you anxious," he said.
"If the incidence of the virus increases, if we have more flocks that suddenly die, it'll be something to be more aware of. But for right now, it's something to know that it's there, but not be scared of."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Magazine
4 days ago
- Time Magazine
Cutting mRNA Research Could Be Our Deadliest Mistake Yet
The U.S. Department of Health and Human Services (HHS) recently announced it will wind down funding for mRNA vaccine development—which could prove to be one of the costliest, deadliest decisions HHS Secretary Robert F. Kennedy Jr. will make during his tenure. HHS has already scaled back access to and recommendations for COVID-19 vaccines—a decision experts are deeply concerned about—and Kennedy's frequently misinformed views on vaccines continue to fan the flames of anti-vaccination attitudes. Now, Kennedy's failure to fully explore the potential of mRNA vaccines could stagnate research that has the potential to save millions of lives around the world. The dark cloud of COVID-19, one of the deadliest infectious disease outbreaks in history, can hardly be thought of as having a silver lining. But the nearest thing to a glimmer of a positive would be that the fast development of COVID-19 vaccines helped prevent many more deaths and led to rapid progress in our understanding and use of mRNA technology. This greater understanding is now being explored as potential preventions or therapies for a wide range of diseases, from H5N1 bird flu and HIV to cancer. Terminating 22 mRNA projects will not only directly set back research on mRNA vaccines for infectious diseases including flu; it will also arguably have negative knock-on effects for researchers the world over exploring personalized treatments for noncommunicable diseases like cancer. Early research on some novel uses of mRNA is promising. For example, a preliminary trial of an mRNA HIV vaccine found that 80% of participants generated neutralizing antibodies, which in theory could help block HIV—pending further research and development. A melanoma mRNA vaccine, when combined with existing treatment, reduced the risk of death or disease recurrence by nearly 50%. (The vaccine is currently being tested further in a full scale Phase 3 clinical trial). Even more amazingly, personalized vaccines—where vaccines are created specifically for an individual using information from their cancer to optimize their immune response—using mRNA technology have even been proposed as a universal vaccine adaptable for all cancers. Read More: The CDC Shooting is a Dark Sign for Science and America Much of the research on personalized mRNA cancer vaccines is in some way indebted to gains in knowledge made from COVID-19 research, and it stands to reason that pulling such a large amount of funding from mRNA projects will slow down further progress in these areas. Approximately $500 million worth of research funding would almost certainly have advanced the scientific community's fundamental understanding of how, and to what extent, mRNA technology works and how it could be applied to prevent and fight disease. Also problematic is the manner in which HHS under Kennedy conveys their decisions. In announcing the funding withdrawal, HHS states it 'will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.' This implies that mRNA vaccines have not been properly or transparently tested—which is not true. The safety of COVID-19 mRNA vaccines has been demonstrated in numerous studies and systematic evidence reviews. Like pretty much all vaccines and treatments, mRNA vaccines are not without side effects, but evidence shows that any adverse events are nearly always mild and short-lived. COVID-19 vaccines have already saved millions of lives globally, with mRNA vaccines accounting for a significant majority of all doses administered in many countries. Kennedy's claim that 'mRNA technology poses more risk than benefits' is almost farcical in light of scientific evidence. Moreover, the whole purpose of clinical research is to test whether new scientific innovations—like novel applications of mRNA into different diseases—are safe and effective in the first place. Kennedy has long spoken of how we need more evidence and testing on mRNA vaccines, and so it is painfully ironic that he is pulling funding for research which would enable the scientific community to do just that. Read More: An mRNA Melanoma Vaccine Shows Promise Perhaps most concerning is the caliber of evidence upon which decisions with such massive implications are being made. In an HHS announcement of the termination of mRNA projects, Kennedy claims 'the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.' The truth is, initial vaccines and booster doses have been shown to be very effective against reducing infection, hospitalization, and death from COVID-19. Kennedy does not even provide links or citations to systematic reviews or meta-analyses in reputable journals, the gold standard methods for scientific evidence. Rather, he simply links to an online evidence review which cherry picks studies searching only for the harms—and not the overall safety, effectiveness, or cost-benefit analysis—of the mRNA vaccines. The report does not describe the methods used to select and review studies, nor does it appear itself to have been peer-reviewed by other scientists. It almost certainly wouldn't be publishable in a scientific journal, yet it is being used as evidence to justify the fate of half a billion dollars of research funds. This is another example of how fringe viewpoints on mRNA technology, instead of the best available scientific evidence, are under Kennedy and HHS becoming the new mainstream. The U.S. has been at the forefront of developing mRNA technology for the past few decades, from the Nobel Prize-winning research of professors Katalin Kariko and Drew Weissman at the University of Pennsylvania on mRNA, to the key role of U.S.-based pharmaceutical companies in vaccine production and rollout. Perhaps other countries, companies, and funding sources will offset this funding loss and lead the development of mRNA vaccine innovations. Large investments are already being made in the U.K. and China, for example. That would be to the detriment of U.S. scientific innovation and progress. Kennedy is right to scrutinize the potential overreach of the pharmaceutical industry, and to ensure their research and development is ethical and transparent. However, his seemingly personal war against "Big Pharma" and ideological opposition to mRNA risks stunting research that could one day help prevent the next pandemic or even provide cures for hitherto incurable cancers.


USA Today
4 days ago
- USA Today
8 ways to treat deep vein thrombosis
When most of us think of a serious medical emergency, we usually think of sudden events such as heart attacks, strokes or serious injuries from a car crash. But some threats develop quietly, with subtle symptoms that can take time to develop into a life-threatening crisis. One such danger is deep vein thrombosis, a blood clot that forms deep within the body and can travel to the lungs, sometimes becoming fatal. And deep vein thrombosis doesn't discriminate. It can start in a young adult after a long flight just as easily as it can occur in someone in their 60s recovering from surgery. Understanding what this condition is, why it occurs and how it's treated can help you prevent it or at least recognize warning signs in yourself or someone you love. What is deep vein thrombosis? Deep vein thrombosis, or DVT, occurs when a blood clot forms in a deep vein – most often in the legs, though it can also happen in an arm, explains Dr. Lawrence Hofmann, a physician and professor of interventional radiology at Stanford School of Medicine. The clot, or thrombus, is made of fibrin, platelets, white blood cells and some red blood cells. When the clot remains in your limb, it can cause swelling, cramping, warmth, aching, skin discoloration and engorged surface veins, Hofmann says, "but when the blood clot moves from your legs to your lungs, it's called a pulmonary embolism and can be very dangerous and even life-threatening.' While DVT is more common in people 55 and older, it "affects around 900,000 people each year in the United States" across a wide range of ages, says Dr. Scott Cameron, section head of vascular medicine at Cleveland Clinic. Blood clotting is normal. But here's why some blood clots turn dangerous, experts say. What causes deep vein thrombosis? No single factor causes DVT. Rather, it usually results from a 'perfect storm' of three issues, Hofmann says. These include slowed blood flow (venous stasis), vessel wall injury (endothelial damage) and thickened blood (hypercoagulability). 'You don't have to have all three to get a blood clot, but the more you have, the higher the risk,' he explains. These issues can arise from many situations, including "genetic disorders that make a person's blood thick," says Dr. Anahita Dua, a vascular surgeon at the Mass General Brigham Heart & Vascular Institute; as well as extended hospital stays, trauma, long periods of immobility like on a long plane journey or car ride, a recent surgery or pregnancy. Lifestyle factors and medical conditions can also play a role. These include obesity, smoking, heart disease, inflammatory bowel disease and hormone therapies. 'Cancer is another major risk factor for DVT,' Cameron notes, because tumors and some cancer treatments can increase clotting activity in the blood. 'And once a patient has experienced a clot, their chances of recurrence remain elevated for up to 10 years,' Cameron adds. Aspirin is a blood thinner. Depending on your health condition, that can be good or bad. How is deep vein thrombosis usually treated? Though DVT can be intimidating and its complications sometimes life-threatening, early recognition and treatment greatly improve outcomes. Symptoms like swelling, pain or warmth in one leg can lead to a diagnostic ultrasound and prompt initiation of treatment, which allows many patients to recover safely. The cornerstone of treatment is anticoagulants, or blood thinners, which reduce the risk of new clots and help the body gradually break down the existing clot. 'The clot starts to dissolve based on enzymes produced by your vein wall,' Hofmann explains. For clots that persist and cause ongoing swelling, procedures like angioplasty and stenting help doctors physically open the vein or remove the obstruction. Minimally invasive catheter-based procedures are also sometimes recommended, Cameron says. Compression stockings, early mobilization and lifestyle interventions like weight management and avoiding smoking can also help treat or prevent DVT. Ultimately, Dua says, "the care a patient with DVT receives is determined by where the clot is, how extensive it is, what caused it and if they can take blood thinners safely."


Fast Company
7 days ago
- Fast Company
What lake sediment cores reveal about metal pollution in the Adirondacks
Lush forests and crisp mountain air have drawn people to New York's Adirondack Mountains for centuries. In the late 1800s, these forests were a haven for tuberculosis patients seeking the cool, fresh air. Today, the region is still a sanctuary where families vacation and hikers roam pristine trails. However, hidden health dangers have been accumulating in these mountains since industrialization began. Tiny metal particulates released into the air from factories, power plants and vehicles across the Midwest and Canada can travel thousands of miles on the wind and fall with rain. Among them are microscopic pollutants such as lead and cadmium, known for their toxic effects on human health and wildlife. For decades, factories released this pollution without controls. By the 1960s and 1970s, their pollution was causing acid rain that killed trees in forests across the eastern U.S., while airborne metals were accumulating in even the most remote lakes in the Adirondacks. As paleolimnologists, we study the history of the environment using sediment cores from lake bottoms, where layers of mud, leaves, and pollen pile up over time, documenting environmental and chemical changes. In a recent study, we looked at two big questions: Have lakes in the Northeast U.S. recovered from the era of industrial metal pollution, and did the Clean Air Act, written to help stop the pollution, work? Digging up time capsules On multiple summer trips between 2021 and 2024, we hiked into the Adirondacks' backcountry with 60-pound inflatable boats, a GPS and piles of long, heavy metal tubes in tow. We focused on four ponds—Rat, Challis, Black and Little Hope. In each, we dropped cylindrical tubes that plunge into the darkness of the lake bottom. The tubes suction up the mud in a way that preserves the accumulated layers like a history book. Back in the lab, we sliced these cores millimeter by millimeter, extracting metals such as lead, zinc and arsenic to analyze the concentrations over time. The changes in the levels of metals we found in different layers of the cores paint a dramatic picture of the pristine nature of these lakes before European settlers arrived in the area, and what happened as factories began going up across the country. A century plagued by contamination Starting in the early 1900s, coal burning in power plants and factories, smelting and the growing use of leaded gasoline began releasing pollutants that blew into the region. We found that manganese, arsenic, iron, zinc, lead, cadmium, nickel, chromium, copper, and cobalt began to appear in greater concentrations in the lakes and rose rapidly. At the same time, acid rain, formed from sulfur and nitrogen oxides from coal and gasoline, acted like chemical shovels, freeing more metals naturally held in the bedrock and forest soils. The result was a cascade of metal pollution that washed down the slopes with the rain, winding through creeks and seeping into lakes. All of this is captured in the lake sediment cores. As extensive logging and massive fires stripped away vegetation and topsoil, the exposed landscapes created express lanes for metals to wash downhill. When acidification met these disturbed lands, the result was extraordinary: Metal levels didn't just increase, they skyrocketed. In some cases, we found that lead levels in the sediment reached 328 parts per million, 109 times higher than natural preindustrial levels. That lead would have first been in the air, where people were exposed, and then in the wildlife and fish that people consume. These particles are so small that they can enter a person's lungs and bloodstream, infiltrate food webs, and accumulate in ecosystems. Then, suddenly, the increase stopped. A public outcry over acid rain, which was stripping needles from trees and poisoning fish, led to major environmental legislation, including the initiation of the Clean Air Act in 1963. The law and subsequent amendments in the following decades began reducing sulfur dioxide emissions and other toxic pollutants. To comply, industries installed scrubbers to remove pollutants at the smokestack rather than releasing them into the air. Catalytic converters reduced vehicle exhaust, and lead was removed from gasoline. The air grew cleaner, the rain became less acidic, and our sediment cores show that the lakes began to heal through natural biogeochemical processes, although slowly. By 1996, atmospheric lead levels measured at Whiteface Mountain in the Adirondacks had declined by 90%. National levels were down 94%. But in the lakes, lead had decreased only by about half. Only in the past five years, since about 2020, have we seen metal concentrations within the lakes fall to less than 10% of their levels at the height of pollution in the region. Our study is the first documented case of a full recovery in Northeast U.S. lakes that reflects the recovery seen in the atmosphere. It's a powerful success story and proof that environmental policy works. Looking forward But the Adirondacks aren't entirely in the clear. Legacy pollution lingers in the soils, ready to be remobilized by future disturbances from land development or logging. And there are new concerns. We are now tracking the rise of microplastics and the growing pressures of climate change on lake ecosystems. Recovery is not a finish line; it's an ongoing process. The Clean Air Act and water monitoring are still important for keeping the region's air and water clean. Though our findings come from just a few lakes, the implications extend across the entire Northeast U.S. Many studies from past decades documented declining metal deposition in lakes, and research has confirmed continued reductions in metal pollutants in both soils and rivers. In the layers of lake mud, we see not only a record of damage but also a testament to nature's resilience, a reminder that with good legislation and timely intervention, recovery is possible. Sky Hooler is a PhD student in environmental science at the University at Albany, State University of New York.